Background Receptor activator of nuclear factor-κB ligand (RANKL) is essential for osteoclast
differentiation, activation, and survival. The fully human monoclonal antibody denosumab (…

… Mease, Kivitz, and Siegel have stock ownership or options in Amgen. Drs. Ory, Salonen,
Rubenstein, and Sharp were compensated for reading radiographs in this study. …

ContextIn vitro studies have shown that celecoxib inhibits cyclooxygenase 2 (COX-2) but not
COX-1, suggesting that this drug may have anti-inflammatory and analgesic activity without …

Objective To assess the efficacy and safety of rilonacept (Interleukin‐1 [IL‐1] Trap), a long‐acting
and potent inhibitor of IL‐1, in patients with cryopyrin‐associated periodic syndromes (…

Objective To evaluate the clinical response, safety, and tolerability of a single intraarticular
injection of anakinra in patients with symptomatic osteoarthritis (OA) of the knee. Methods …

Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative …

Background Patients who have had inadequate response to tumour necrosis factor inhibitors
have fewer treatment options and are generally more treatment refractory to subsequent …

… Mease, Genovese, Gladstein, and Kivitz have received consulting fees, speaking fees, and/or
honoraria from Bristol-Myers Squibb (less than $10,000), and Dr. Mease has also received …

… Kivitz has been a clinical … Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ. Risk
of adverse events including serious infections in rheumatoid arthritis patients treated with …

OBJECTIVE: This study compared the immunogenicity of influenza and pneumococcal
vaccines in adult patients with rheumatoid arthritis (RA) receiving adalimumab or placebo. …